- Previous Close
7.66 - Open
7.71 - Bid 7.45 x --
- Ask 7.50 x --
- Day's Range
7.41 - 7.72 - 52 Week Range
5.00 - 21.20 - Volume
23,300 - Avg. Volume
65,738 - Market Cap (intraday)
943.697M - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-0.98 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Biomm S.A. operates as a biotechnology company in Brazil. The company offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA. Biomm S.A. was founded in 2001 and is headquartered in Nova Lima, Brazil.
www.biomm.comRecent News: BIOM3.SA
View MorePerformance Overview: BIOM3.SA
Trailing total returns as of 12/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOM3.SA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOM3.SA
View MoreValuation Measures
Market Cap
971.61M
Enterprise Value
935.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.35
Price/Book (mrq)
3.19
Enterprise Value/Revenue
7.56
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-63.30%
Return on Assets (ttm)
-11.32%
Return on Equity (ttm)
-36.82%
Revenue (ttm)
123.78M
Net Income Avi to Common (ttm)
-78.35M
Diluted EPS (ttm)
-0.98
Balance Sheet and Cash Flow
Total Cash (mrq)
170.07M
Total Debt/Equity (mrq)
43.69%
Levered Free Cash Flow (ttm)
-68.87M